AstraZeneca drops Skyrizi rival after seeing R&D timeline spiral

AstraZeneca is abandoning a play for the inflammatory bowel disease (IBD) market. After seeing clinical trial timelines spiral, the Anglo-Swedish drugmaker has stopped development of a would-be rival to products sold by AbbVie and Johnson & Johnson.